Latest IR information
IR News
- 2025.10.07
- SymBio Submits Clinical Trial Application to the UK’s MHRA for the Phase 3 Global Study Evaluating IV Brincidofovir for the Treatment of Adenovirus Infection After HSCT
- 2025.10.06
- SymBio Initiates Global Phase 3 Trial of IV Brincidofovir for the Treatment of Adenovirus Infection Post-HSCT, Following Regulatory Approval in Three Major European Countries
- 2025.10.01
- Notice Regarding the Monthly Exercise Status of the 58th and 65th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued through Third-Party Allotment
- 2025.10.01
- Notice Regarding Notice of the Large Volume Exercise of the 65th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third-Party Allotment
- 2025.09.30
- IV Brincidofovir for Treatment of Adenovirus Infection after HSCT Receives Orphan Drug Designation from Japan’s Ministry of Health, Labour and Welfare